Renalytix AI PLC Stifel 2020 Healthcare Conference
13 November 2020 - 6:00PM
RNS Non-Regulatory
TIDMRENX
Renalytix AI PLC
13 November 2020
Renalytix AI plc
("RenalytixAI" or the "Company")
RenalytixAI to Participate in the Stifel 2020 Healthcare
Conference
NEW YORK, November 13, 2020 - Renalytix AI plc (LSE : RENX)
(NASDAQ: RNLX), an artificial intelligence-enabled in vitro
diagnostics company, focused on optimizing clinical management of
kidney disease to drive improved patient outcomes and advance
value-based care , today announced the company will be
participating in the upcoming Stifel Virtual Healthcare
Conference.
RenalytixAI's management is scheduled to present on Tuesday,
November 17 at 10:40 a.m. Eastern Time. Interested parties may
access a live and archived webcast of the presentation on the
"Investors" section of the company website at
www.investors.renalytixai.com .
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker Tel: 020 7710 7600
)
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584
391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and 1 out of 2 people with very low kidney
function who are not on dialysis do not know they have CKD*. Kidney
disease is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
*
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally.
RenalytixAI's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, patient stratification for drug clinical trials, and
drug target discovery. For more information, visit
www.renalytixai.com .
Disclosure Information
Renalytix AI plc uses filings with the Securities and Exchange
Commission, its website ( www.renalytixai.com ), press releases,
public conference calls, public webcasts and its social media
accounts as means of disclosing material non-public information and
for complying with its disclosure obligations under Regulation
FD.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAFFAFDNEFAA
(END) Dow Jones Newswires
November 13, 2020 02:00 ET (07:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024